Invention Grant
- Patent Title: Optimized HCV full-length infectious cell culture systems and applications thereof
-
Application No.: US15522745Application Date: 2015-10-23
-
Publication No.: US10280404B2Publication Date: 2019-05-07
- Inventor: Jens Bukh , Yiping Li , Santseharay Ramirez Almeida
- Applicant: Hvidore Hospital , Københavns Universitet
- Applicant Address: DK Hvidovre DK København
- Assignee: Hvidovre Hospital,Københavns Universitet
- Current Assignee: Hvidovre Hospital,Københavns Universitet
- Current Assignee Address: DK Hvidovre DK København
- Agency: Schwegman Lundberg & Woessner, P.A.
- Priority: DK201470659 20141028
- International Application: PCT/DK2015/050325 WO 20151023
- International Announcement: WO2016/066171 WO 20160506
- Main IPC: C12N7/00
- IPC: C12N7/00 ; C12Q1/70
Abstract:
The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.
Public/Granted literature
- US20180201905A1 OPTIMIZED HCV FULL-LENGTH INFECTIOUS CELL CULTURE SYSTEMS AND APPLICATIONS THEREOF Public/Granted day:2018-07-19
Information query
